ManagementManagementManagementManagement
  • About LIXTE
    • Management
    • Board of Directors
    • Forward-Looking Statements
  • Product Development
  • Publications
  • Investor Information
  • About LIXTE
    • Management
    • Board of Directors
    • Forward-Looking Statements
  • Product Development
  • Publications
  • Investor Information
    • Investor Alerts
menu toggle
Close
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 30, 2023 8:30am EDT

Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy

Apr 24, 2023 8:30am EDT

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

Apr 04, 2023 8:30am EDT

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

Feb 14, 2023 1:50pm EST

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

Feb 07, 2023 12:16pm EST

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

Nov 30, 2022 8:05am EST

LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference

Oct 13, 2022 8:30am EDT

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

Jun 21, 2022 8:30am EDT

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

Jun 15, 2022 8:30am EDT

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

Apr 14, 2022 6:45pm EDT

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Contact

LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180
Pasadena, CA 91101

General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Fax: (631) 982-5050
info@lixte.com

LIXTE Biotechnology Holdings, Inc. is publicly traded as LIXT.

About LIXTE

  • About LIXTE
  • Management
  • Board of Directors
  • Forward-Looking Statements

Development

  • Product Development

Publications

  • Publications

Investor Information

  • Investor Information
  • Email Alerts
Back to top
© 2023 LIXTE Biotechnology Holdings, Inc. (LIXTE). All Rights Reserved. Site by Third Eye Industries
    Close